TAVR Sustains Its Promise in Low-Risk Patients, But the Journey Is Far From Over. Thourani VH, Yadav PK, Prendergast B. J Am Coll Cardiol 2022;79:897-899.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Thourani VH, Yadav PK, Prendergast B. TAVR Sustains Its Promise in Low-Risk Patients, But the Journey Is Far From Over. J Am Coll Cardiol 2022;79:897-899.
PMID: 35241223